Jim Collins Prescribes Five Micro-Cap Names to Build Portfolio Immunity
Source: JT Long of Streetwise Reports' Special Situations  (10/8/15)
In a volatile macroeconomic world, micro caps can offer some immunity as they move based on company news rather than front page headlines. But you have to pick your companies carefully. In this interview with Streetwise Reports' Special Situations, Jim Collins, founding partner of The Portfolio Guru, shares the names of a handful of companies he found in his travels to the LD Micro Conference and beyond. More >

Advocacy and Technology Move Stem Cell Research Forward: Bernie Siegel of the Genetics Policy Institute
Source: Dan Levy of The Life Sciences Report  (10/7/15)
Regenerative medicine through stem cell technology is a source of hope for many suffering from ailments including Alzheimer's disease, diabetes, spinal cord injury and cancer. While new therapeutic options are continually in development, progress has, until recently, been hampered by political and medical ethics arguments. Because of patient advocacy, new technologies are now advancing, from development of an artificial pancreas to the hope of culturing intact human organs. In this interview with The Life Sciences Report, Bernie Siegel, founder and executive director of the Genetics Policy Institute, describes recent progress and developments in the regenerative medicine universe. More >

Piper Jaffray's Brett Wong: How to Profit from Government Mandates in Biofuels
Source: JT Long of The Energy Report  (10/6/15)
New proposed EPA requirements for the renewable fuel standard program, combined with challenging sugarcane harvests in South America, could increase demand for biodiesel, creating opportunity in a struggling energy sector. In this interview with The Energy Report, Piper Jaffray Analyst Brett Wong names a growing company that could profit from government mandates. More >

Andrew Pullar's Plan: Go Long, Set Goals with World-Class Assets
Source: Brian Sylvester of The Gold Report  (10/5/15)
Andrew Pullar, CEO of The Sentient Group, a private equity fund, says his plan for investment success is all about identifying companies with long-life, low-cost, world-class assets and supporting them through to production. In this interview with The Gold Report, Pullar plots the course for a handful of what he believes are world-class mining assets. More >

Survival Secrets from Colorado Resource Investing Front Lines
Source: JT Long of The Gold Report  (10/1/15)
Top experts and select companies traveled to Colorado last week for a pair of conferences focused on the survivors in the natural resource mining sector. The Gold Report reached out to some of the discerning voices there and asked whether the barrage of headlines from the Federal Reserve and China impacted the mood, and what companies they would be following up on when they returned to their offices. While the Precious Metals Summit was geared toward development-stage companies and the Denver Gold Forum was mostly populated by large, producing mining companies, everyone seemed fixated on survival. For those of us watching from home, experts we talked to were kind enough to name some of the standout companies they saw in boothland. More >

BTIG's Hartaj Singh's Advice for Biotech Investors: 'Hold Your Powder' 'til Winter
Source: Gail Dutton of The Life Sciences Report  (9/30/15)
While waiting for biotech stocks to correct, investors should be focused on performing due diligence, says Hartaj Singh of investment firm BTIG LLC. Growth in company valuations has outpaced sales for several years, but the coming weeks will see rapid fluctuations as the two begin to realign. In this interview, Singh shares his predictions for the rest of 2015 with The Life Sciences Report, and identifies several companies to hold for potentially big returns. More >

Breakthrough Potential: BriaCell Therapeutics Takes Its Cancer Vaccine to the Next Level
Source: Gail Dutton of The Life Sciences Report  (9/30/15)
Immuno-oncology has the potential to not only transform medicine, but also to become a multibillion-dollar market for a drug developer with the right team and the right compound. In this interview with The Life Sciences Report, BriaCell Therapeutics Corp. executives Joseph Wagner, Charles Wiseman and Saeid Babaei describe their company's new therapeutic, which has generated stunning results in early trials, making "breakthrough" designation by the FDA a realistic possibility. More >

These Six Gold Companies Could Create Exceptional Wealth Sooner Than You Think: Jeb Handwerger
Source: JT Long of The Gold Report  (9/28/15)
For smart investors watching the gold-Dow ratio rather than mainstream media headlines, this is an exciting time to be a precious metals investor. The world seems to be conspiring to push the price of gold higher, with continued zero interest rates, Chinese stock market volatility and more unrest in the Middle East. In this interview with The Gold Report, Gold Stock Trades Editor Jeb Handwerger lays out his short list of junior mining companies that have been actively adding value, and that will be in demand when all eyes are on the sector. More >

Two Signs We May Have Reached Capitulation: Common Stock Warrants Watcher Dudley Baker
Source: JT Long of The Gold Report  (9/24/15)
Looking to leverage the upside of inevitable rising precious metals prices without the risk of buying mining company stocks? In this interview with The Gold Report, Dudley Baker, founder of Common Stock Warrants, shares his approach to evaluating companies for longevity and the opportunities warrants in those companies might play in the right circumstances.
More >

Sunridge Is Now Good to Go at Its Asmara VMS Project in Eritrea
Source: Kevin Michael Grace of The Gold Report  (9/24/15)
It's been a very active decade filled with milestones for Sunridge Gold, and now following the September signing of a comprehensive permitting agreement with its partner, the government of Eritrea, the Canadian junior is set to begin production in 2016. In this interview with The Gold Report, President and CEO Michael Hopley discusses the riches of his company's copper, gold, zinc and silver deposits and looks forward to becoming as successful as Nevsun has been. More >

Slaying Oncology and Infectious Disease with Immunotherapy's Double-Edged Sword: Maxim Group's Jason McCarthy
Source: George S. Mack of The Life Sciences Report   (9/23/15)
Maxim Group Equity Analyst Jason McCarthy has developed a biotechnology theme that leverages immunotherapy platforms serving both cancer and infectious disease indications. It's an elegant dual premise that enables one side to fund development of the other, and it seems to be working beautifully for companies and their shareholders. In this interview with The Life Sciences Report, McCarthy explains the principle and describes five companies proving up the model's profitability. More >

Extra: Jeb Handwerger Predicts New Wave of Lithium and Graphite Winners in Wake of Tesla Deal
Source: JT Long of The Energy Report  (9/22/15)
Don't buy things that are trending on Twitter or the front page of USA Today, warns Gold Stock Trades publisher Jeb Handwerger. Buy them when they are unloved and on the back page. In this interview with The Energy Report, he singles out the unloved companies that could become media darlings in the coming boom in energy metals, uranium and—eventually—oil sectors. And he stresses the importance of the single most important commodity in the investing space ever—time. More >

Silver Investor David Morgan: Conspiracy Facts Show Metal Prices Have to Rise
Source: JT Long of The Gold Report  (9/21/15)
Even in a frozen metals price market, it only takes one event to shake off the paper manipulation keeping prices below what supply and demand fundamentals of a free market would dictate. And when that correction comes, it could happen quickly. In this interview with The Gold Report, The Morgan Report Publisher David Morgan shares his favorite ways to own leverage to metal prices upside while protecting against junior mining risk. More >

When Gold Escapes the Pork Belly Trap, Casey's Louis James Wants to Own These Seven Companies
Source: JT Long of The Gold Report  (9/17/15)
When is gold more than a commodity? When it is recognized as the last safe haven in a volatile world. In this interview with The Gold Report, Casey Research Senior Analyst Louis James warns that "there are so many fragile points around the global economy today any jolt can cause follow-on crashes, collapses—all the volatility we have come to know and love since 2008." To prepare for the inevitable, James shares the seven advanced junior names that he thinks could move up fast when the hard reality of gold's value starts hitting the bottom line. More >

No Fed Rate Hike Good for Gold, Bad Sign for Economy
Source: JT Long, The Gold Report   (9/17/15)
The much-anticipated decision by the Federal Reserve Board at the Sept. 17 meeting to hold interest rates near zero was met in the resource community with a mixture of relief and disappointment. The 9-to-1 vote citing global economic pressure on inflation left open the possibility of a hike at the December meeting. The Gold Report asked the experts in the resource sector what this means for precious metals and oil prices, and what signs they are looking for that a different outcome will be announced in December. More >

Fallen Biotech Angels to Arise: John McCamant and Jay Silverman of the Medical Technology Stock Letter
Source: George S. Mack of The Life Sciences Report   (9/16/15)
It's all about data for John McCamant and Jay Silverman of the Medical Technology Stock Letter, and right now it's festival time as we approach the busy season of market-moving catalysts and milestones. From now until December, biotech investors will be focused on the press releases, webinars and scientific presentations that serve as a vitality tonic for the entire biotech industry. In this interview with The Life Sciences Report, McCamant and Silverman give a detailed picture of their growth theories on six biotech stocks that could reap many multiples on invested capital over the next few years. More >

Alert: Veteran Investment Strategist Joe McAlinden Cautions Fed to Get Out of Business of Manipulating Stock Markets
Source: Gordon Holmes of Streetwise Reports  (9/16/15)
With the markets in whiplash mode, Joe McAlinden, founder of McAlinden Research Partners and former chief global strategist with Morgan Stanley Investment Management, believes volatility is going to stick around for a while. In fact, he just announced that we might see a correction double of what we've had so far. In this interview with Streetwise Reports, McAlinden bucks conventional wisdom and lays out his investing strategy for this period of market uncertainty. More >

Thomas Drolet Warns of a Coming Grand Canyon of Uranium Supply Deficit and Shares Three Ways to Profit by It
Source: JT Long of The Energy Report  (9/15/15)
A Grand Canyon of supply deficit is opening up in the uranium markets, with 66 nuclear reactors under construction globally and more restarting in Japan. As Russia and China shore up their supply chains in Kazakhstan and elsewhere, the rest of the world could be scrambling for new sources to keep the lights on. In this interview with The Energy Report, Thomas Drolet, head of Drolet & Associates Energy Services, illuminates junior companies in the Athabasca Basin, southern Alberta and South America that could be strategic sources for countries shoring up domestic supply and for majors that need replacement resources. More >

Veteran Investment Strategist Joe McAlinden Reverses View, Predicts Recovery for Gold, Oil and Housing
Source: Gordon Holmes of The Gold Report  (9/14/15)
With the markets in whiplash mode, Joe McAlinden, founder of McAlinden Research Partners and former chief global strategist with Morgan Stanley Investment Management, believes volatility is going to stick around for a while, and we might see a correction double of what we've had so far. In this interview with The Gold Report, McAlinden bucks conventional wisdom to argue that an interest rate hike is good for gold and oil, and lays out his investing strategy for this period of market uncertainty. More >

The Promise of Plants in Pharmaceutical Production: iBio's Robert Erwin
Source: Gail Dutton of The Life Sciences Report  (9/9/15)
The growing need for recombinant proteins for vaccines and therapeutics is causing the biotech industry to look beyond vat fermentation and cell cultures for protein expression systems that, like iBio Inc.'s iBioLaunch technology, can increase yields quickly, safely and inexpensively. In this interview with The Life Sciences Report, iBio's President Robert L. (Bob) Erwin describes the iBioLaunch technology and what it offers to drug developers and investors. More >

CAR T-Cell Therapeutics: Alan Leong of BioWatch Looks Beyond the Buzz for Solid Early-Stage Plays
Source: Gail Dutton of The Life Sciences Report  (9/9/15)
CAR T-cell therapies show amazing potential in treating blood cancers, but there's a lot of work to do before the cells are ready for commercialization. Alan Leong, senior analyst with BioWatch, tells The Life Sciences Report about the latest in CAR T-cell therapeutics and how some companies are hedging their bets by developing bispecific antibodies. He also describes the reality behind the growing excitement in regenerative medicine, and what investors should know about some very innovative, but often overlooked, small companies. More >

NexGen Energy: A Bold New Uranium Venture for a World in Short Supply
Source: Peter Byrne of The Energy Report  (9/8/15)
NexGen Energy Ltd. has a strong, well-focused uranium project located in the cornucopia of the Athabasca Basin. Without hype, CEO Leigh Curyer and Corporate Development Manager Travis McPherson, part of an experienced team of "pure-play uranium professionals," make the case for investment in a project with obvious legs. More >

Flinders CEO Blair Way: What Tesla Needs to Know About the Graphite Sector
Source: Special to The Gold Report  (9/8/15)
Tesla's moves toward manufacturing auto and home storage has set off a buzz of misunderstandings and opportunities in the graphite space as some 40 TSX and ASX junior miners position themselves to meet anticipated increased future demand for this critical mineral. In this interview with The Gold Report, Flinders Resources CEO and President Blair Way shares the four factors to consider when analyzing a graphite company. Warning: It is a very different proposition than investing in a gold company. More >

Could a President Trump Put People Back to Work and Help the Dollar?: ShadowStats' John Williams
Source: JT Long of The Gold Report  (9/4/15)
Despite happy economic reporting from the government, ShadowStats' John Williams warns that underlying problems from the crash of 2008 were never addressed, leaving the United States in a recession papered over by sleight of hand and a workforce redefined out of existence. Bottom line? "Holding gold is the best way to weather the storm that is coming when the fundamental weakness of the stock market and the U.S. dollar becomes apparent," Williams tells The Gold Report. More >

Resource Capital Funds Backs Callinex's Strategy near HudBay Operations
Source: Kevin Michael Grace of The Gold Report  (9/3/15)
Manitoba's Flin Flon Greenstone Belt has yielded VMS discoveries resulting in dozens of mines. Callinex Mines has been a big part of that success for almost a century and believes it has the properties that will become the district's latest winners. In this interview with The Gold Report, Callinex President and CEO Max Porterfield explains how high-grade assays and proximity to existing producers could lead to his company discovering the ore that HudBay will soon need. More >